# Query Results

**Query:** subsidiaries history

**Timestamp:** 20251020_025631

**Top K:** 5

**Results Found:** 5

---

## Result 1

**Similarity Score:** 0.0079 | **Semantic:** 0.0000 | **Keyword:** 0.0263 | **Rerank:** -9.1165

**Source:** ion-beam-applications-ebribab-statistics-valuation-metrics.md

**Chunk ID:** 8

**Content:**

```
ct 17, 2025, 5:35 PM CET
 * [Overview](https://stockanalysis.com/quote/ebr/IBAB/)
 * [Financials](https://stockanalysis.com/quote/ebr/IBAB/financials/)
 * [Statistics](https://stockanalysis.com/quote/ebr/IBAB/statistics/)
 * [Dividends](https://stockanalysis.com/quote/ebr/IBAB/dividend/)
 * [History](https://stockanalysis.com/quote/ebr/IBAB/history/)
 * [Profile](https://stockanalysis.com/quote/ebr/IBAB/company/)
 * [Chart](https://stockanalysis.com/quote/ebr/IBAB/chart/)
```

---

## Result 2

**Similarity Score:** 0.3898 | **Semantic:** 0.5569 | **Keyword:** 0.0000 | **Rerank:** -9.6947

**Source:** iba-sa-ottignies-louvain-la-neuve-1348-be0428750985.md

**Chunk ID:** 3

**Content:**

```
(https://www.companyweb.be/en/payment-history)
 * [ Integrations Connect to your software ](https://www.companyweb.be/en/integrations)
```

---

## Result 3

**Similarity Score:** 0.3352 | **Semantic:** 0.4789 | **Keyword:** 0.0000 | **Rerank:** -9.8296

**Source:** iba-reports-full-year-2023-results.md

**Chunk ID:** 12

**Content:**

```
BA and SCK CENs joint venture PanTera for the production of actinium-225, with collaborations secured with supplier TerraPower and post-period end, with Bayer and another undisclosed customer
 * Post-period end, Dosimetry product offering and US footprint strengthened with acquisition of Radcal Corporation, an X-ray imaging specialist
 * B Corp recertification ongoing
 * Henri de Romree appointed as Deputy CEO
```

---

## Result 4

**Similarity Score:** 0.3370 | **Semantic:** 0.4814 | **Keyword:** 0.0000 | **Rerank:** -9.8994

**Source:** iba-reports-full-year-2023-results-iba-group.md

**Chunk ID:** 23

**Content:**

```
ion or installation at the end of the period
 * Continued good progress of IBA and SCK CENs joint venture PanTera for the production of actinium-225, with collaborations secured with supplier TerraPower and post-period end, with Bayer and another undisclosed customer
 * Post-period end, Dosimetry product offering and US footprint strengthened with acquisition of Radcal Corporation, an X-ray imaging specialist
 * B Corp recertification ongoing
 * Henri de Romree appointed as Deputy CEO
```

---

## Result 5

**Similarity Score:** 0.0050 | **Semantic:** 0.0000 | **Keyword:** 0.0167 | **Rerank:** -9.9196

**Source:** ion-beam-applications-ebribab-statistics-valuation-metrics.md

**Chunk ID:** 12

**Content:**

```
o | n/a 
P/OCF Ratio | 119.11 
PEG Ratio | n/a 
[Financial Ratio History](https://stockanalysis.com/quote/ebr/IBAB/financials/ratios/)
## Enterprise Valuation
The stock's EV/EBITDA ratio is 7.79, with an EV/FCF ratio of -102.50. EV / Earnings | 21.58 
---|--- 
EV / Sales | 0.62 
EV / EBITDA | 7.79 
EV / EBIT | 10.07 
EV / FCF | -102.50 
## Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.57.
```

---

